HOLD - Do not add fresh capital; maintain existing position to collect dividend carry while waiting for technical confirmation, earnings validation, and a clearer macro environment

• PEG ratio of 1.83 indicates aggressive growth expectations baked into the 14.5x P/E multiple, making it a warning light rather than a floor
• Q3 FY26 5.6% YoY growth is reacceleration to roughly half the historical 8-12% run rate, not a return to trend
• Q2 FY26 EPS dipped to $2.93 before bouncing to $3.80, revealing earnings volatility inconsistent with a smooth compounder
• Golden cross unconfirmed: 50 SMA at $182.48 versus 200 SMA at $192.39 with $10 gap creates asymmetric downside risk if 50 SMA rolls over
• MACD at 4.04 represents less than half the prior August peak of 8.5, indicating fading momentum within a broken structure rather than early innings
• October 1 gap of 15.8% on 29 million shares has unidentified fundamental catalyst, making the move suspect rather than durable
• Volume collapsed 82% from the gap day with five straight declining sessions, suggesting evaporating conviction rather than healthy consolidation
• Conservative risk-reward is closer to 1:1.2 (downside to $118 is $78 or 40%; upside to $291 is $94 or 48%) not the claimed 1:6
• 10-year yields at highest since 2002 represent structural DCF multiple compression and one to two quarter lag on IT discretionary spending
• GenAI tailwind faces competitive cannibalization risk from IBM Consulting, Deloitte, Cognizant, Infosys, and hyperscalers competing for same budgets
• Stock demonstrated ability to fall 50% in six months (December 2025 to June 2026), with no structural reason it cannot happen again
• Dividend carry of 37 basis points is a bonus, not the strategy; the strategy is capital preservation

→ vs aggressive: PEG ratio of 1.83 directly contradicts the 'deep value' framing; a low P/E in technology services is a warning light, not automatically a bargain

→ vs aggressive: Q3 FY26's 5.6% YoY is half the historical 8-12% growth rate; one quarter does not a trend make and calling it 'reacceleration' or 'bending back up' overstates the case

→ vs aggressive: MACD at 4.04 is less than half the mid-August peak of 8.5; 'early innings of a fresh leg' requires belief in a breakout the data does not support

→ vs aggressive: Declining volume is 'narrative, not data'; 82% volume collapse with unidentified catalyst for the October 1 gap means conviction is evaporating, not consolidating

→ vs aggressive: The 1:6 risk-reward is deeply misleading; using the actual 52-week range of $118.15 to $291.09 with current price at $196.64 yields closer to 1:1.2

→ vs aggressive: 'Higher rates don't kill profitable consultants' is half-true; 10-year yields at highest since 2002 compress DCF multiples and slow corporate IT discretionary spending with a one to two quarter lag

HOLD at $196.64 — maintain existing position, collect 3.54% dividend yield, wait for add-on triggers ($200 break on volume >10M or confirmed 50/200 golden cross for 2+ sessions), exit at $192 stop on volume >7M

• 14.5x trailing P/E on 26% ROE franchise with net cash and 3.54% yield is high quality at reasonable price, not a screaming buy and not a value trap
• Risk-reward is roughly symmetric on 52-week basis: downside to May-June low ~$122 is ~$74 (38%), upside to December 2025 high ~$282 is ~$85 (43%), closer to 1:1.1 than the aggressive's claimed 1:6
• Q3 FY26 reacceleration at 5.6% YoY is mixed signal amid demonstrated earnings lumpiness (Q2 FY26 EPS $2.93, Q4 FY25 special charges $615M) — one quarter does not establish trajectory
• 50 SMA at $182.48 and 200 SMA at $192.39 are ~$10 apart and converging; buying ahead of cross treats possible as probable; trader should wait for confirmation
• Declining volume from 28.98M to 5.12M after 15.8% gap is normal consolidation, but unknown catalyst behind the gap means don't add aggressively
• Macro is a constraint not catalyst: 10-year yields at highest since 2002 and 96% probability of zero Fed cuts in 2026 partially priced into 14.5x P/E discount multiple
• GenAI TAM is real but competitive landscape (IBM, Deloitte, Cognizant, hyperscalers) and potential billable hour cannibalization make 24-month thesis genuinely unknowable
• Existing position already absorbs setup risk; adding capital tightens stop but doesn't improve win rate; $192 stop is real loss risk, not free insurance
• Position sizing (1.5x ATR, 1-2% NAV), stop at $192, and add-on/exit triggers are appropriately calibrated — HOLD is active choice to collect dividend while waiting for technical confirmation
• Next fundamental catalyst is Q4 FY26 earnings print; reassess then for continued reacceleration with GenAI bookings acceleration alongside confirmed golden cross

→ vs aggressive: The 1:6 risk-reward cited uses favorable resistance (October 1 high ~$30 upside) against unfavorable support ($4.64 stop), ignoring the actual 52-week range of $118.15-$291.09 where current price at $196.64 is midpoint — honest ratio is ~1:1.1, not 1:6

→ vs aggressive: Buying ahead of an unconfirmed cross with 'starter' position sizing is double exposure to a setup that hasn't resolved; existing position already sized to 1.5x ATR risk budget

→ vs aggressive: Treating the $192 stop as 'free insurance' understates it — if triggered on macro-driven or gap-driven event after adding, the trader has increased concentration right before a loss, the worst sequence in position management

→ vs conservative: Treating HOLD as passive is incorrect — it is an active choice to maintain exposure within defined risk envelope while collecting 3.54% dividend carry on net-cash 26% ROE franchise

→ vs conservative: Underweighting the structural quality of the business: 26% ROE, net cash balance, and 3.54% yield are real return components that compound over time, not consolation for an incomplete bull case